ArticleBiomolecules & biomedicine2026
ZNF469 drives TGF-β1/SMAD3-mediated extracellular matrix regulation in pulmonary fibrosis.
Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding fibroblast activation: Transcriptional networks in hepatic stellate cells and across fibrotic organs (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary fibrosis is characterized by persistent activation of lung fibroblasts and excessive extracellular matrix (ECM) deposition; however, the transcriptional mechanisms sustaining this activated state remain poorly understood. Given the established profibrotic role of zinc finger protein 469 (ZNF469) in other mesenchymal lineages, we investigated its function in lung fibroblasts using an integrated functional and transcriptomic approach. We found that ZNF469 depletion attenuated key features of fibroblast activation, including proliferation, migration, and contractile capacity, concomitantly reducing collagen production and deposition. Mechanistically, combined transcriptomic profiling and Cleavage Under Targets and Release Using Nuclease (CUT&RUN) assays revealed that ZNF469 modulates ECM-associated transcriptional regulation, demonstrating preferential occupancy at the promoters of key collagen genes, such as collagen type I alpha 1 chain (COL1A1) and collagen type III alpha 1 chain (COL3A1). Furthermore, we demonstrated that transforming growth factor-β1 (TGF-β1) stimulated ZNF469 expression in a SMAD family member 3 (SMAD3)-dependent manner, with CUT&RUN further revealing SMAD3 occupancy at the ZNF469 promoter. Importantly, ZNF469 depletion blunted TGF-β1-induced collagen production, indicating that ZNF469 contributes to the profibrotic effects of the TGF-β1/SMAD3 axis. Finally, we underscored the clinical relevance of ZNF469 by analyzing bulk and single-cell RNA sequencing data from patients with idiopathic pulmonary fibrosis and systemic sclerosis. ZNF469 was found to be upregulated in fibrotic lung tissues, particularly within the activated fibroblast lineage, and correlated with key ECM gene signatures. Our findings collectively support a model wherein the TGF-β1/SMAD3/ZNF469 axis contributes significantly to ECM gene regulation and fibroblast activation, thereby positioning ZNF469 as a critical profibrotic factor and a promising therapeutic target in pulmonary fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.